Here's why the Volpara (ASX:VHT) share price is up 6% today

The Volpara (ASX: VHT) share price is gaining today after the company released its quarterly results. Let's take a look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Volpara Health Technologies Ltd (ASX: VHT) shares are gaining today after the company released its quarterly results. At the time of writing, the Volpara share price is up 6.25%, trading at $1.36 apiece.

Volpara is a health technology software company, providing an integrated breast care platform to deliver personalised breast care. Let's take a closer look at the New Zealand-based company's latest results.

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Fourth-quarter results

The company released its results for the fourth quarter of the 2021 financial year this morning, garnering a positive reaction from investors.

Good news from the company included a record cash income from customer receipts, equalling NZ$5.4 million. That figure represents a 15% increase compared to the fourth quarter of 2020.

The company's subscription-based receipts were also up, raking in NS$18.3 million – a 39% year on year increase.

Volpara also announced increases in its unaudited cash receipts for the full year ending 31 March 2021, up 20% year on year.

Its net operating cash outflow was better than the company's internal forecasting, and it ended the quarter with $32.2 million cash in the bank.

Volpara's earnings before interest, tax, depreciation and amortisation (EBITDA) came in at a loss of NZ$3,432,000.

Today is the second time Volpara's share price has reacted positively to its results for this quarter. On 20 April, the Volpara released a business update on the fourth quarter, which also saw its share price rise.

Unfortunately, its gains didn't hold that day, and the Volpara share price ended the session trading 4.2% lower than the previous close.

Commentary from management

Volpara CEO Dr Ralph Highnam commented on the results, saying:

Our achievements in [the 2021 financial year] are a powerful endorsement of what we stand for as a company and the strength and commitment of our industry to keep saving families from cancer, no matter what else is going on.

We look forward to continuing to accelerate out of COVID-19 in [the 2022 financial year].

Volpara share price snapshot

Currently, the Volpara share price is down 3% year to date, although it's up 8% over the last 12 months.

The company has a market capitalisation of around $321 million, with approximately 251 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends VOLPARA FPO NZ. The Motley Fool Australia has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a young scientist looking stressed out while working on a computer in a lab.
Broker Notes

What's Bell Potter's updated view on CSL shares?

Will the new tariffs impact CSL according to Bell Potter?

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Are Cogsgate shares a buy, hold or sell after rocketing 12% higher yesterday?

This broker thinks there could be more growth to come.

Read more »

woman in lab coat conducting testing.
Healthcare Shares

Is this battered ASX biotech stock ready to rocket higher?

Brokers are upbeat and see upside of up to 125%!

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Why are CSL shares struggling to regain momentum?

Analysts have widely considered the shares to be oversold for some time now.

Read more »

Happy man working on his laptop.
Healthcare Shares

This ASX healthcare stock is up 70% in a year and climbing again today

Another strong quarter keeps the Cogstate stock in focus.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX healthcare stock could more than double according to Canaccord Genuity

It's shaping up as a big year for this drug developer.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Broker Notes

Why beaten down CSL shares now offer 'long-term appeal'

A leading expert gives his outlook for CSL’s beaten down shares.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why Neuren shares are rebounding on Wednesday after a brutal 2026 sell-off

Neuren shares jump after DAYBUE STIX expands across the US.

Read more »